Immunogenicity and safety study of GSK Biologicals’ candidate malaria vaccine given at 6, 7.5 and 9 months of age in co-administration with measles, rubella and yellow fever (YF) vaccines followed by a booster of the malaria vaccine.

Trial Identifier: 200596
Sponsor: GlaxoSmithKline
Start Date: May 2017
Primary Completion Date: March 2018
Study Completion Date: October 2020
Condition: Parasite Infections

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Ghana Kintampo, Ghana
Ghana Kumasi, Ghana, NONE